

Atezolizumab Study ML39345

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



**Serious and disabling adverse effects**



**Other adjustments**



Atezolizumab Study ML39345

### SCORE

**CURATIVE**




Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Sarcoma

Therapeutic Indication: For adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS).

Experimental Arm: Atezolizumab

Control Arm: Single arm

